ABCL vs VRDN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABCL · AbCellera Biologics$9.69 ▼ 7.45%
VRDN · Viridian Therapeutics$29.96 ▼ 4.71%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABCL +171.4%
- VRDN -6.5%
Head to head
| Metric | ABCL | VRDN |
|---|---|---|
| Price | $9.69 | $29.96 |
| Change today | ▼ 7.45% | ▼ 4.71% |
| Market cap | $3.16B | $3.40B |
| Return, 3 months | -8.7% | +24.7% |
| Return, year to date | +183.3% | -3.7% |
| Return, 1 year | +176.1% | -1.3% |
| P/E (TTM) | – | – |
| P/B | 3.0 | 7.0 |
| P/E percentile vs own 5y | 6th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +18.8% | -63.5% |
| Net profit growth (YoY) | +28.6% | -192.5% |
| Gross margin | – | 94.1% |
| Operating margin | -275.7% | -1,781.4% |
| Net margin | -218.6% | -1,741.9% |
| Return on equity | -14.6% | -115.0% |
| Analyst target vs. price | +99.5% | +34.9% |
| Analyst buy share | 89% | 100% |
| RSI (14) | 34 | 64 |
| 30-day volatility | 80.2% | 64.4% |
| Max drawdown, 1 year | -40.1% | -60.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VRDN is the largest of the group by market value.
- ABCL has returned the most over the past year.
- ABCL is growing revenue fastest.
- ABCL keeps the most profit per dollar of sales.
- VRDN has been the calmest stock over the last 30 days.